Clinical trials: Opiate Abuse
Medication Abuse, Harm Reduction
Clinical Decision Support to Improve System Naloxone Co-prescribing
The objective of this study is to evaluate the impact of a clinical decision support (CDS) alert to facilitate the co-prescribing of naloxone, an opioid overdose reversal agent, with high-risk opioid prescriptions.
- Conditions
- Medication Abuse, Harm Reduction, Opioid Overdose, Opioid Prescribing
- Trial name
- NCT06271668
- Testing
- Naloxone Co-prescribing Clinical Decision Support (CDS)
- Where
- United States
- Volunteers
- 114,272 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Cocaine, Substance Abuse
The Maternal Lifestyle Study (MLS)
This is a longitudinal, multi-site observational study of the long-term effects of a mother's use of cocaine and/or opiates during pregnancy on her infant.
- Conditions
- Cocaine, Substance Abuse, Infant, Newborn, Pregnancy
- Trial name
- MLS (NCT00059540)
- Where
- 5 sites in United States
- Volunteers
- 11,811 people, healthy volunteers welcome
- Sponsor
- NICHD Neonatal Research Network
Asperger's Disorder, Asperger Disorder
QAIAx - SGI/SI Smart Health Cities: Microcity Enclave Program (Quantum SI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360; USPTO EO 9424 Assignment ID: 2101042 / ARN: REEL/FRAME: 76481/0026 - OUSD-R&E, Department of War)
BRIEF SUMMARY A. "What is the purpose of this study?" BACKGROUND. The QAIAx clinical trial (Quantum SI/SGI Public Health Agency), known operationally as the "AI City Hall Project," represents a landmark intergovernmental research…
- Conditions
- Asperger's Disorder, Asperger Disorder, Autism Disorder, Autism
- Trial name
- QAIAx (NCT07661823)
- Testing
- AI City Hall Project (AIhealth4u - Public Health Central), AI City Hall Project (QAIAx Microcity A - AI Public Health Central)
- Where
- United States
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- Veterans Recovery Network Inc.